Annovis Bio, Inc. (ANVS)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 02:00PM EDT. Market open.
| Previous close | 9.85 |
| Open | 9.85 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's range | 9.62 - 10.18 |
| 52-week range | 5.42 - 22.49 |
| Volume | |
| Avg. volume | 244,917 |
| Market cap | 109.452M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
- Zacks
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
- Zacks
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
© 2024 Yahoo. All rights reserved.